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Purpose: To compare the effect of pegaptanib versus ranibizumab on exudative age-related 
macular degeneration (AMD) with small lesion size.
Methods: This is a retrospective study of 81 eyes from 78 patients with exudative AMD treated 
and followed up over 12 months. Patients with baseline best corrected visual acuity (BCVA) 
under 20/400 and with a greatest linear dimension of lesion over 4500 µm were excluded from 
the study. Twenty-six eyes from 25 patients were treated with three consecutive intravitreal 
injections of pegaptanib (IVP group) and 55 eyes from 54 patients were treated with three 
consecutive ranibizumab injections (IVR group). Each therapy was repeated as needed. The 
alteration in BCVA was evaluated in the IVP and IVR groups.
Results: No differences were detected in baseline parameters between the IVP and IVR groups. 
The mean BCVA (logMAR) at month 1, 3, 6 and 12 after the initial treatment was improved 
from baseline in the IVP group (−0.095, −0.17, −0.18 and −0.18, respectively) and in the IVR 
group (−0.077, −0.15, −0.17 and −0.11, respectively), which was statistically significant. There 
was no difference in the change in mean BCVA between IVP and IVR groups at the same time 
periods.
Conclusions: The visual outcome of IVP was equivalent with IVR in exudative AMD with 
small lesion size.
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Introduction
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agent is 
  currently the main treatment for subfoveal choroidal neovascularization (CNV) due 
to age-related macular degeneration (AMD), a leading cause of central visual loss in 
the elderly in industrialized countries.1,2 Currently, there are two anti-VEGF agents 
approved to treat exudative (or neovascular) AMD; pegaptanib sodium, a specific anti-
VEGF165 aptamer and ranibizumab, a nonselective anti-VEGF-A antibody. Previous 
randomized control studies demonstrated a significant improvement in the mean visual 
acuity of exudative AMD patients treated with intravitreal injection of ranibizumab 
(IVR),3–5 while those treated with intravitreal injection of pegaptanib (IVP) showed 
no improvement in the mean visual acuity.6 However, recent reports documented that 
visual loss after 24 months of monthly IVR or at 24 months after IVR with a pro re nata 
(as needed) regimen was associated with abnormalities of retinal pigment epithelium 
(RPE), excessive subretinal fibrosis, and atrophic scar.7,8 We hypothesized that those 
results might be attributable to nonspecific suppression of VEGF, a potent survival 
factor for photoreceptor cells,9 choroidal vascular endothelial cells,10 and RPE11,12 
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thus the subtype-specific anti-VEGF therapy should be 
selected as the main intervention to treat exudative AMD. 
To our knowledge, no study has been published to compare 
the effectiveness between IVP and IVR for exudative AMD 
with respect to lesion size.
In this study, we performed a comparative assessment to 
determine whether the visual outcomes of IVP and IVR were 
different in exudative AMD with relatively smaller lesion 
size and better baseline visual acuity.
Subjects and methods
The records of 185 consecutive exudative AMD patients 
treated by IVP or IVR and followed up over 12 months 
were retrospectively reviewed. All patients received detailed 
ophthalmic examinations, including best corrected visual 
acuity (BCVA) measurements, slit lamp biomicroscopy 
of their fundi, color fundus photography, fluorescein 
angiography (FA), indocyanine green angiography (ICG) 
and optical coherence   tomography (OCT). Patients with 
baseline BCVA under 20/400, those with a greatest linear 
dimension (GLD) of lesion over 4500 µm, and patients 
who had received previous therapy for AMD were excluded 
from the study. Patients with past histories of retinal vessel 
occlusion, uveitis, rhegmatogenous retinal detachment or 
glaucoma were also excluded.   Following these protocols, 
81 eyes of 78 patients were included for analysis.
From October 2008 to March 2009, all patients were 
treated by IVP. After ranibizumab became available in 
Japan (April 2009), IVR was selected as the main inter-
vention and IVP was used for patients with a risk of brain 
infarction. In the IVP group (26 eyes of 25 patients), 
all patients received three consecutive IVP injections at 
6 weekly intervals as the initial treatment. In the IVR 
group (55 eyes of 53 patients), all patients received three 
consecutive monthly IVRs for the initial treatment as 
previously described. Patients were then followed up with 
monthly examinations of the lesions13,14 and additional IVP 
or IVR was performed as needed, namely when sustained 
or recurrent serous retinal detachment, macular edema or 
hemorrhage was recognized by fundoscopy or OCT. Two 
patients in the IVP group received IVR 6 months after the 
initial IVP since the physician considered that IVP was not 
effective enough to reduce CNV lesions (including serous 
retinal detachment and macular edema). For those patients, 
we excluded the data for BCVA at 12 months after the 
initial treatment from the analysis. However, we counted 
each IVR as one treatment in the analysis with respect to 
the number of treatments.
For statistical analysis, we first compared gender, age, 
BCVA, GLD at baseline between the IVP and IVR groups. 
Changes in BCVA were then compared until 12 months 
after the initial treatment. Visual acuities were determined 
using a Landolt C chart, and were converted to logarithm 
of the minimum angle of resolution (logMAR) values for 
  calculation. An F-test for homoscedasticity of variance fol-
lowed by a two-tailed t-test or a chi-square test was performed 
to compare any two groups. P values of 0.05 or less were 
considered to be statistically significant.
Results
The data summary of AMD patients treated by IVP or IVR 
is shown in Table 1. No baseline parameter showed signifi-
cant difference between the IVP and IVR groups. The F-test 
indicated homoscedasticity of variance in BCVA between the 
IVP and IVR groups (F-value = 0.49, P = 0.49). In the time 
course analysis, the mean BCVA was significantly improved 
compared with the baseline BCVA in each group (Figure 1). 
Although the IVR group showed a decrease in the mean 
BCVA at the 12 month follow-up, there was no significant 
difference between the IVP group and the IVR group at any 
time period measured. For BCVA measurements, about 
25%–30% of patients gained more than 0.3 LogMAR during 
12 months after the initial therapy, whereas about 10% of 
patients lost more than 0.3 LogMAR during the same time 
period in both groups (Figure 2). There was no significant 
difference in the proportion of BCVA change in the IVP 
Table 1 Data summary of the participants treated by intravitreal 
injection of pegaptanib or ranibizumab
IVP (n = 26) IVR (n = 55) P value
Male/female 19/6 35/18 0.37†
Age (years) 72.2 ± 11.0 74.3 ± 9.7 0.40*
Age range (years) 50–89 51–92
Lesion type (eyes) 
Predominantly classic 
Minimally classic 
Occult with no classic 
With PCV
 
6 
6 
4 
10
 
8 
11 
14 
22
 
0.65†
Baseline BCVA (LogMAr) 0.44 ± 0.37 0.50 ± 0.36 0.49*
BCVA range 20/400–20/20 20/400–20/20
Baseline GLD (µm) 2337 ± 1014 2825 ± 912 0.10*
GLD range (µm) 686–4290 810–4232
Number of injections/year 4.6 ± 2.2 5.1 ± 2.3 0.39*
Number of injections/year  
range
3–9 3–11
Notes: Values are presented as mean ± SD when applicable. *Unpaired t-test; 
† chi-square test.
Abbreviations: iVP, intravitreal injection of pegaptanib; iVr, intravitreal injection 
of ranibizumab; BCVA, best corrected visual acuity; GLD, greatest linear dimension; 
PCV, polyploidal choroidal vasculopathy.
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that secondary visual loss, occurring at or after month 24 of 
IVR, was associated with abnormalities of the retinal pigment 
epithelium (RPE), subretinal fibrosis and atrophic scar,7,8 which 
suggested the risk of nonspecific suppression of VEGF by 
ranibizumab. Efforts were made to decrease the number of 
IVR injections to treat exudative AMD,5,13,14 but the use of 
IVP may be considered as an alternative therapy for exudative 
AMD with small lesion size.18 VEGF165 is known as the major 
inducer of abnormal blood vessel growth and leakage in wet 
AMD,19,20 but all VEGF-A isoforms are key angiogenic and 
neuroprotective factors for several tissues.9–12,21–23 Nonspecific 
inhibition of  all VEGF-A isoforms might reduce the ability to 
tolerate several kind of stresses in the photoreceptor, RPE and 
normal choroidal endothelial cells. The abnormalities of RPE 
and atrophic scars found in the cases treated with monthly IVR 
might reflect the lack of VEGF-mediated neuroprotection for 
the cells. Interestingly, we found that four cases showed atro-
phic scars and three cases showed subfoveal fibrosis in the IVR 
group while these findings were not observed in the IVP group 
in the present study. To avoid the risk of oversuppression of 
physiological VEGF effects, many studies have been conducted 
to reduce the number of IVR injections.5,13,14 A recent prospec-
tive study has demonstrated good visual outcomes of exudative 
AMD patients by using IVP as a maintenance therapy after 
IVR.24 Other studies reported that good visual stability was 
obtained with IVP monotherapy in selective cases, particularly 
those in the early stage.25,26 Since the pathogenesis of CNV 
is thought to be associated with VEGF165 and VEGF121,27,28 
IVP monotherapy may not be sufficient to suppress all CNV . 
However, our results have demonstrated that IVP could be a 
useful modality of choice for the patients with exudative AMD 
having small lesion size.
The major limitation of the present study was the non-
randomized and retrospective nature of the study and the 
relatively small number of subjects. Hence, it is important 
to evaluate the results of randomized control trials for IVP 
and IVR with a large number of subjects to determine the 
comparative effectiveness of these therapies, particularly for 
exudative AMD with small lesion size. Further investigations 
will be needed to determine the correct indications for use 
of IVP and IVR for exudative AMD.
In conclusion, IVP may be an effective therapy for BCVA 
over a 12 month period in patients with exudative AMD and 
lesions less than 4500 µm in size.
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Figure 1 Changes in the best corrected visual acuity (BCVA) after intravitreal 
pegaptanib or ranibizumab. 
Notes: Squares with solid lines: pegaptanib; Circles with dashed lines: ranibizumab. 
Values represent means ± standard error in the mean. *P , 0.05; **P , 0.005; 
***P , 0.0005 compared to baseline.
Abbreviation: ns, not significant.
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Figure 2 Proportion of the change in the BCVA (LogMAr) between baseline 
and after 12 months of intravitreal pegaptanib or ranibizumab in the exudative 
AMD patients.
group versus the IVR group (P = 0.68). An accumulation of 
subfoveal hard exudates was found in one case in the IVP 
group, whereas four cases showed atrophic scars and three 
cases showed subfoveal fibrosis in the IVR group, and those 
were associated with a deterioration of BCVA 12 months 
after the initial treatment.
Discussion
We compared the effect of IVP versus IVR on exudative 
AMD with relatively small lesion size, and demonstrated that 
the visual outcome was not significantly different between 
the IVP and IVR groups. In other words, IVP was a good 
modality of choice for exudative AMD without severe visual 
disturbance and with smaller GLD at baseline.
Currently, anti-VEGF therapies are the leading modalities 
for exudative AMD.15–17 Many reports demonstrated that IVR 
remarkably attenuated the activity of CNV and improved the 
average visual outcome. However, recent reports have shown 
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